Colorectal And Other GI Cancers
In the Phase 2, multicenter, open-label, single-arm CheckMate -142 trial (n=74), qualified patients received Opdivo 3mg/kg intravenously (IV) every 2 weeks.
Herceptin, a human epidermal growth factor receptor (HER2) inhibitor, is currently approved to treat HER2-overexpressing metastatic breast cancer as a single agent in patients who have received one or more chemotherapy regimens; or in combination with paclitaxel in patients who have not received chemotherapy.
In addition, the FDA has also approved a multigene, next-generation sequencing-based test to identify RAS mutation status of the patient's tumor and help physicians identify patients who will more likely benefit from Vectibix.
Individuals with a family history of CRC in a first-degree relative diagnosed before age 60 should undergo colonoscopy every 5 years beginning at age 40 or 10 years before the age at which their relative was diagnosed.
The researchers administered detailed epidemiologic questionnaires to 2,419 patients age 18 to 74 years with incident invasive CRC, diagnosed from 1997 to 2008.
Doctors were 78% more likely to prescribe a drug to treat metastatic renal cell carcinoma if they'd received a gift or small payment from that drug's manufacturer, compared to physicians who didn't receive any payments.
Keytruda, a programmed death receptor-1 (PD-1)-blocking antibody, recently gained approval for urothelial carcinoma and metastatic non-small cell lung cancer (NSCLC).
Opdivo, a human programmed death receptor-1 (PD-1)-blocking antibody, is already indicated for various renal and urologic cancers, head and neck cancer, lymphoma, skin cancer, and lung cancer.
The researchers found that the use of antibiotics within the previous 4 years wasn't associated with a heightened risk of colorectal adenomas, but long-term use in the past was.
The researchers observed a significant decrease of E-cadherin expression and a significant increased single-cell growth at the invasion front in tumor samples after radiochemotherapy versus primary biopsies of the tumor.
Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.
Colorectal cancer (CRC) rates among those aged 50 and older have fallen 32% since 2000, while deaths from the disease fell by 34%, according to a report published online March 1 in CA: A Cancer Journal for Clinicians.
Young and middle-aged colon cancer patients may be getting chemotherapy more often than is warranted, according to a study published online in JAMA Surgery.
Eisai has announced positive topline results from their Phase 3 trial of lenvatinib (Lenvima), for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
For patients undergoing colorectal cancer (CRC) surgery, CpG island methylator phenotype (CIMP) status predicts survival, according to research published online Jan. 14 in the Journal of Gastroenterology and Hepatology.
The efficacy of NSAIDs, aspirin, and supplements in preventing the recurrence of advanced neoplasia after polyp removal was evaluated in a new study.
In patients with chronic hepatitis C virus (HCV) infection and intermediate stage hepatocellular carcinoma (HCC) who receive transarterial chemoembolization (TACE), the SVR achieved with pegylated-interferon (pegIFN/ribavirin (RBV) treatment markedly improved survival and reduced tumor recurrence, a study presented at The Liver Meeting 2016® concluded.
The investigational oral pentamidine isethionate formulation VLX103 is safe and well tolerated at the once-daily 300mg to 900 mg dose.
For patients taking antiretroviral medications, HIV continues to reside in tissues, and though this may not cause AIDS, it could contribute to the development of unrelated conditions such as cancer and cardiovascular disease, according to research published in the October issue of the Journal of Virology.